Skip to content

InterFuse® S and T for the Treatment of Scoliosis, Spondylolisthesis and Degenerative Disc Disease (DDD)

A Multi-Center Prospective Study of Vertebral Technologies, Inc. (VTI) InterFuse® S and InterFuse® T for the Treatment of Scoliosis, Spondylolisthesis and Degenerative Disc Disease.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02659722
Enrollment
200
Registered
2016-01-20
Start date
2014-01-31
Completion date
2019-01-31
Last updated
2016-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Back Pain, Scoliosis

Keywords

INTERVERTEBRAL DISC DEGENERATION, Bone Disease, Musculoskeletal disease, Spinal disease

Brief summary

The primary objective of this prospective, post-market study is to collect data to assess the long term outcome of a broad contact modular interbody device in the form of the InterFuse S™ or InterFuse T™ device in patients undergoing long construct fusion for degenerative disc disease and/or scoliosis. Comparisons will be made with published historical data..

Detailed description

The primary objective of this prospective, post-market study is to collect data to assess the long term outcome of a broad contact modular interbody device in the form of the InterFuse S™ or InterFuse T™ device in patients undergoing long construct fusion for degenerative disc disease and/or scoliosis. While there is no concurrent control population, there is ample historical control data to be used for comparison. The study will include up to two hundred (200) patients, up to 10 centers, and provide a prospective evaluation of the InterFuse T and/or InterFuse S Interbody Fusion System. Primary endpoints will be assessed at twelve months post-surgery. All patients enrolled in the study will be followed for at least 24 months.

Interventions

DEVICEInterFuse

TRansforaminal or Posterior placement of an InterFuse S and/or T device, in combination with approved posterior fixation

Sponsors

Vertebral Technologies, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1\. The patients has a planned fusion construct of at least five levels and will have the InterFuse (S) or (T) planned for L5-S1 and/or L4-L5. 2\. The patient has documented conservative (non-operative) treatment for at least 6 months. 3\. The patient has a VAS score of ≥ 60 mm for Back and/or Leg. 4. The patient has an ODI ≥ 40%. 5. The general condition of the patient is appropriate for surgery, as evaluated by the Investigator. 6\. The patient is willing and able to comply with study requirements. 7. The patient has agreed to participate in the study

Exclusion criteria

* 1\. The patient has undergone any prior spinal fusion surgery at the proposed treatment level(s). Previous non-fusion surgery at the proposed treatment level(s) is acceptable. 2\. The patient has osteoporosis or severe osteopenia as determined by the Investigator. A clinical SCORE calculator may be utilized for females over 40 years of age. 3\. The patient has grade 2 or higher spondylolisthesis or retrolisthesis at the affected level(s). 4\. The patient has known neoplastic disease other than skin cancer. 5. The patient has a Body Mass Index (BMI) of greater than 40; BMI = wt (kg)/ht2 (m2). 6\. The patient has an active infection. 7. The patient is pregnant or is planning on becoming pregnant in the next two years. 8\. The patient is mentally ill or has a history of drug abuse or severe depression/ psychosocial issues. 9\. The patient has a known allergy to polyether ether ketone (PEEK), stainless steel or tantalum. 10\. The patient is currently enrolled in an investigational spine study. 11. The patient has rheumatoid arthritis, ankylosing spondylitis or other autoimmune disease. 12\. The patient has symptomatic fibrous arachroiditis.

Design outcomes

Primary

MeasureTime frameDescription
disc height retention24 monthsloss of restored disc height over time
Complications24 monthsMigration, subsidence, hardware lossening and others
Lordosis24 monthsretention of restored degree of lordosis
Fusion24 monthsSpeed of fusion

Secondary

MeasureTime frameDescription
Scoliosis Research Society (SRS) Scores24 monthsScoliosis Research Society Scores
Complications II24 monthsre-admission rate and re-operation rate
Pain and function Scores24 monthsVisual Analog Scale (VAS) leg and back (at rest and active)

Countries

United States

Contacts

Primary ContactJeff Felt, MD
jfelt@vti-spine.com612-708-4838
Backup ContactBen A. Wasscher, MBA
bwasscher@vti-spine.com763-218-4311

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026